ESMC's Net Loss Widens Sharply Amid Revenue Dip, Going Concern Doubts

TL;DR

**ESMC is bleeding cash and explicitly warns of going concern risk; stay far away unless you're a vulture investor.**

AI Summary

ESCALON MEDICAL CORP (ESMC) reported a significant increase in net loss for the three months ended September 30, 2025, reaching $239,852, a substantial rise from the $32,217 net loss in the same period of 2024. This deterioration was primarily driven by a loss from operations of $202,751 in Q3 2025, compared to a loss of $26,955 in Q3 2024, and a new 'other expense' of $32,797. Total revenues decreased by 3.8% to $2,675,321 from $2,781,346 year-over-year, with product revenues declining from $2,651,291 to $2,536,881. Research and development expenses increased significantly by 53.4% to $216,098 from $140,859. The company's total assets decreased to $4,581,639 as of September 30, 2025, from $4,993,059 as of June 30, 2025, while total liabilities also decreased to $2,906,384 from $3,077,952. Despite a positive net cash provided by operating activities of $85,008, the company explicitly stated 'substantial doubt regarding the Company's ability to continue as a going concern' due to recurring losses and adverse cash-to-current liabilities ratios.

Why It Matters

ESMC's escalating net loss and explicit 'going concern' warning are critical for investors, signaling severe financial instability and potential for significant capital erosion. The 3.8% revenue decline, coupled with a 53.4% surge in R&D expenses without immediate returns, suggests a challenging path to profitability. This financial distress could impact employees through job insecurity and customers through potential disruptions in product availability or service. In a competitive healthcare market, ESMC's struggles could allow larger, more stable medical device companies to gain market share, further pressuring ESMC's long-term viability.

Risk Assessment

Risk Level: high — The company explicitly states 'substantial doubt regarding the Company's ability to continue as a going concern' for the next twelve months. This is supported by a net loss of $239,852 for the three months ended September 30, 2025, a significant increase from $32,217 in the prior year, and recurring historical losses from operations.

Analyst Insight

Investors should avoid ESMC given the explicit going concern warning and deteriorating financial performance, including a widening net loss and declining revenues. Existing shareholders should consider divesting to mitigate further losses, as the company's future is highly uncertain without significant capital infusion or a dramatic turnaround.

Financial Highlights

revenue

$2,675,321

total Assets

$4,581,639

net Income

-$239,852

eps

-$0.03

revenue Growth

-3.8%

Revenue Breakdown

Key Numbers

• $239,852 — Net loss for Q3 2025 (Increased significantly from $32,217 in Q3 2024)
• $2,675,321 — Total revenues for Q3 2025 (Decreased by 3.8% from $2,781,346 in Q3 2024)
• $202,751 — Loss from operations for Q3 2025 (Increased from $26,955 in Q3 2024)
• $216,098 — Research and development expenses for Q3 2025 (Increased by 53.4% from $140,859 in Q3 2024)
• $4,581,639 — Total assets as of September 30, 2025 (Decreased from $4,993,059 as of June 30, 2025)
• $85,008 — Net cash provided by operating activities for Q3 2025 (Positive, but company still has going concern issues)
• 7,415,329 — Shares of common stock outstanding (As of November 13, 2025)
• $0.03 — Basic loss per share for Q3 2025 (Increased from $0.01 in Q3 2024)

Key Players & Entities

• ESCALON MEDICAL CORP (company) — registrant
• Sonomed, Inc. (company) — wholly owned subsidiary
• Escalon Digital Solutions, Inc. (company) — wholly owned subsidiary
• Sonomed IP Holdings, Inc. (company) — wholly owned subsidiary
• United States Food and Drug Administration (regulator) — regulates company products
• Securities and Exchange Commission (regulator) — regulates financial filings
• FASB (regulator) — accounting standard setter
• Chief Executive Officer (person) — Company's CODM
• Chief Operating Officer (person) — Company's CODM

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company has stated substantial doubt regarding its ability to continue as a going concern due to recurring losses and adverse cash-to-current liabilities ratios. This is a significant risk for investors.
• Increasing Net Loss [high — financial]: Net loss for Q3 2025 was $239,852, a sharp increase from $32,217 in Q3 2024. This deterioration is driven by a widening loss from operations and new other expenses.
• Declining Revenues [medium — financial]: Total revenues decreased by 3.8% to $2,675,321 in Q3 2025 from $2,781,346 in Q3 2024, with product revenues also seeing a decline.
• Rising R&D Expenses [medium — operational]: Research and development expenses surged by 53.4% to $216,098 in Q3 2025 from $140,859 in Q3 2024, impacting profitability without a corresponding revenue increase.
• Decreasing Asset Base [medium — financial]: Total assets decreased to $4,581,639 as of September 30, 2025, from $4,993,059 as of June 30, 2025, indicating a potential contraction or asset disposal.

Industry Context

Escalon Medical Corp operates in the medical device sector, which is characterized by innovation, regulatory hurdles, and competitive pressures. Companies in this space often require significant R&D investment to develop new products and maintain market share. The current economic climate may also impact healthcare spending and device adoption rates.

Regulatory Implications

As a medical device company, ESMC is subject to stringent regulations from bodies like the FDA. Any product development or sales are contingent on regulatory approval, and compliance failures can lead to significant penalties and operational disruptions.

What Investors Should Do

1. Monitor R&D spending effectiveness: Assess if the 53.4% increase in R&D expenses leads to future revenue growth or product innovation.
2. Evaluate going concern statement: Investors should closely watch management's strategies to address the substantial doubt about the company's ability to continue as a going concern.
3. Analyze revenue trends: Investigate the drivers behind the 3.8% revenue decline and the specific reasons for the drop in product revenues.
4. Scrutinize expense management: Understand the nature of the new 'other expense' and the reasons for the increased loss from operations.

Key Dates

• 2025-09-30: End of Q3 2025 — Period for which financial results show a significant increase in net loss and operational challenges.
• 2025-11-13: Shares of common stock outstanding reported — Provides the current share count for per-share calculations and market capitalization context.

Glossary

Going Concern

An assumption that a company will continue to operate for the foreseeable future, typically at least 12 months. If there is substantial doubt about this, it must be disclosed. (ESMC has explicitly stated substantial doubt about its ability to continue as a going concern, highlighting significant financial distress.)

Loss from Operations

The total expenses of a company minus its total revenues, excluding any non-operating income or expenses. (This metric shows a significant increase in ESMC's operating losses, indicating core business challenges.)

Other Expense

Expenses that are not directly related to the company's primary business operations. (The introduction of 'other expense' in Q3 2025 contributed to the overall increase in net loss.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, Escalon Medical Corp has experienced a significant deterioration in its financial performance. Total revenues declined by 3.8%, while the net loss widened dramatically from $32,217 to $239,852. This is exacerbated by a substantial 53.4% increase in research and development expenses, contributing to a larger loss from operations. The company's balance sheet also shows a decrease in total assets.

Key Financial Figures

• $0.001 — ate: 7,415,329 shares of common stock, $0.001 par value outstanding as of November 13
• $1,038,537 — d and outstanding (liquidation value of $1,038,537 and $1,025,531) 645,000 645,000 Common
• $1,025,531 — ng (liquidation value of $1,038,537 and $1,025,531) 645,000 645,000 Common stock, $0.001
• $133,000 — ithin prior period deferred revenue was $133,000 and $1 08,000, respectively for the thr
• $1 — eriod deferred revenue was $133,000 and $1 08,000, respectively for the three-mont

Filing Documents

• esmc-20250930.htm (10-Q) — 570KB
• esmc_20250930-10qex311.htm (EX-31.1) — 10KB
• esmc_20250930-10qex312.htm (EX-31.2) — 9KB
• esmc_20250930-10qex321.htm (EX-32.1) — 5KB
• esmc_20250930-10qex322.htm (EX-32.2) — 4KB
• 0001628280-25-052330.txt ( ) — 4494KB
• esmc-20250930.xsd (EX-101.SCH) — 29KB
• esmc-20250930_cal.xml (EX-101.CAL) — 55KB
• esmc-20250930_def.xml (EX-101.DEF) — 191KB
• esmc-20250930_lab.xml (EX-101.LAB) — 504KB
• esmc-20250930_pre.xml (EX-101.PRE) — 366KB
• esmc-20250930_htm.xml (XML) — 461KB

Financial Information

PART I Financial Information Item I. Unaudited Condensed Consolidated Financial Statements 4 Condensed Consolidated Balance Sheets as of September 30, 2025 (unaudited) and June 30, 2025 5 Condensed Consolidated Statements of Operations for the three-month periods ended September 30, 2025 and 2024 (unaudited) 6 Condensed Consolidated Statements of Shareholders' Equity for the three-month periods ended September 30, 202 5 and 202 4 (unaudited) 7 Condensed Consolidated Statements of Cash Flows for the three-month periods ended September 30, 202 5 and 202 4 (unaudited) 8 Notes to the Condensed Consolidated Financial Statements (Unaudited) 9

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 18

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 23

Controls and Procedures

Item 4. Controls and Procedures 9

Other Information

PART II Other Information

Exhibits

Item 6. Exhibits 23 PART 1. FINANCIAL INFORMATION Item I. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ESCALON MEDICAL CORP. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS September 30, 2025 June 30, 2025 (Unaudited) ASSETS Current assets: Cash $ 615,791 $ 545,835 Restricted cash 256,582 256,550 Accounts receivable 1,412,003 1,667,394 Less: allowance for credit losses ( 75,177 ) ( 164,499 ) Accounts receivable, net 1,336,826 1,502,895 Inventories 1,746,324 2,142,263 Other current assets 267,060 164,394 Total current assets 4,222,583 4,611,937 Property and equipment, net 35,752 34,589 Right-of-use assets 235,636 253,953 License and patent, net 24,880 29,792 Other long term assets 62,788 62,788 Total assets $ 4,581,639 $ 4,993,059 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Current portion of note payable $ 38,329 $ 40,708 Current portion of EIDL loan 3,232 3,370 Accounts payable 1,180,382 1,387,192 Accrued expenses 747,375 633,422 Related party accrued interest 112,389 112,389 Current portion of operating lease liabilities 76,381 86,521 Deferred revenue 277,468 327,919 Other short term liabilities 93,799 93,727 Total current liabilities 2,529,355 2,685,248 Note payable, net of current portion 78,308 85,761 Operating lease liabilities, net of current portion 160,422 168,015 EIDL loan, net of current portion 138,299 138,928 Total liabilities 2,906,384 3,077,952 Commitments and Contingencies (Note 10) Stockholders' equity: Series A convertible preferred stock, $0.001 par value; 2,000,000 shares authorized; 2,000,000 shares issued and outstanding (liquidation value of $1,038,537 and $1,025,531) 645,000 645,000 Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding 7,415 7,415 Additional paid-in capital 69,702,043 69,702,043 Accumulated deficit ( 68,679,203 ) ( 68,439,351 ) Total stockholders' equity 1,675,255 1,915,107 Total liabilities and sto

View Full Filing

View this 10-Q filing on SEC EDGAR